-
2026-10-28
IND Approval: GenSci136 Advances into Sj?gren's SyndromeLearn More
-
2026-10-22
Phase 3 trial in China successfully confirms ACARIZAX? safety and efficacy in patients with house dust mite allergyLearn More
-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More
-
2024-05-26
NMPA Approves Genakumab Injection for Clinical Trial Commencementwhich marks the initiation of bioequivalence studies for the new formulation of Genakumab Injection
Learn More
-
2024-05-17
Jintrolong? PEG-rhGH from GenSci highlighted at ECE 2024Jintrolong? PEG-SOMATROPIN was highlighted during the Growth Hormone Research Society (GRS) symposium at the largest endocrine event in Europe
Learn More
-
2024-04-11
R&D Progress: NMPA Approves Genakumab to the MarketMajor R&D Progress
Learn More
-
2023-12-22
GenSci Launches Global Innovation Hub in ShanghaiThe Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges
Learn More